Skip to main content

Table 1 Patient recruited (PT) and expression datasets retrieved (PR) for this study.

From: Reconstruction and functional analysis of altered molecular pathways in human atherosclerotic arteries

Patient (PT)/Profile (PR)

Sex

Age (Years)

Tissue sample

Pathology/Lesion type

Co-morbidities

Pharmacological therapy

Plasma lipid/Stenosis/ICR

PT1

M

50

LAD

Ischemic/VII

Hypothyroidism

D;AAP;AC;HYR

+/> 75%/5

PT2

F

68

LAD;AB

Ischemic/VII

None

D;AC

+/> 75%/4.6

PT3

M

66

LAD;AB

Ischemic/VII

Cholecystectomy

AAP;HYR

=/> 75%/5

PT4

M

64

LAD;AB

Ischemic/VII

None

D;HYR

+/> 75%/5.2

PT5

M

64

LAD;AB

Ischemic/VI

PAH

D;ST;AAP;HYR

+/> 75%/4.9

PT6

M

42

LAD;AB

Ischemic/VII

None

D;HYR

+/> 75%/5.3

PT7

M

53

LAD;AB

Ischemic/VII

Stone Kidney

D;HYR;AAP

+/> 75%/5.1

PT8

M

68

LAD

Ischemic/VI

None

D;HYR;AAP

+/> 75%/5.2

PT9

M

46

LAD;AB

DCM/ctrl

None

D;AC

+/-/4.6

PT10

M

48

LAD;AB

DCM/ctrl

Kidney pathology

D;AC

=/-/4.7

PT11

F

55

LAD;AB

DCM/ctrl

Thyroidectomy

D;AC;CDR

=/-/4.5

PT12

F

59

LAD;AB

DCM/ctrl

None

BB;AC;AAP

=/-/3.2

PT13

M

63

LAD;AB

DCM/ctrl

None

ACEH;D;AC

=/-/3.6

PT14

M

53

LAD;AB

DCM/ctrl

None

ACEH;D;AAP

+/-/3.8

PT15

M

62

LAD

DCM/ctrl

Gilbert's syndrome

AAP

=/-/3.5

PT16

M

61

LAD

DCM/ctrl

None

ACEH;ST

=/-/3.5

PT17

F

59

LAD

DCM/ctrl

None

ACEH;AC;AAP

=/-/4.3

PT18

F

41

LAD

DCM/ctrl

None

D

=/-/3.9

PT19

M

70

AB

Ischemic/VII

T2D

D;HYR;SI

+/> 75%/5

PT20

M

67

AB

Ischemic/VII

Mitral insufficiency

None

=/> 75%/4.3

PT21

F

82

AB

Ischemic/VII

HY

None

+/> 75%/4.6

PT22

M

63

AB

Ischemic/VI

None

None

=/> 75%/4.8

PT23

M

75

AB

Ischemic/VI

None

ACEH;HYR

+/> 75%/5.2

PT24

M

64

AB

Ischemic/VII

PD

HYR;D;LD

+/> 75%/5.1

PT25

M

75

AB

Ischemic/VII

T2D;HY

SI;HYR

+/> 75%/5.2

PT26

M

57

AB

Ischemic/VII

T2D;HY

SI;HYR

+/> 75%/5.5

PT27

M

66

AB

Ischemic/VII

HY

HYR

+/> 75%/5.2

PT28

M

69

AB

Ischemic/VII

HY

HYR

+/> 75%/5

PT29

M

51

AB

Ischemic/VI

None

None

=/> 75%/4.8

PT30

F

78

AB

Ischemic/VII

HY

HYR

+/> 75%/4.5

PT 31

M

75

AB

Ischemic/VI

None

None

=/> 75%/5.1

PR32*

M

67

Carotid

Ischemic

Acute bronchitis

NA

NA/75%/NA

PR33*

M

67

Carotid

Ischemic

Acute bronchitis

NA

NA/71%/NA

PR34*

F

63

Carotid

Ischemic

CAD;T2D;HY

NA

NA/75%/NA

PR35*

F

63

Carotid

Ischemic

CAD;T2D;HY

NA

NA/50%/NA

PR36*

F

59

Carotid

Ischemic

HY;HYCH

NA

NA/75%/NA

PR37*

F

59

Carotid

Ischemic

HY;HYCH

NA

NA/83%/NA

PR38*

F

71

Carotid

Ischemic

CAD;T2D;HY;HYCH;AD

NA

NA/70%/NA

PR39*

F

71

Carotid

Ischemic

CAD;T2D;HY;HYCH;AD

NA

NA/83%/NA

PR40†

NA

NA

Coronary

Normal

NA

NA

NA

PR41†

NA

NA

Coronary

Normal

NA

NA

NA

PR42†

NA

NA

Coronary

Normal

NA

NA

NA

PR43‡

M

NA

Coronary

Normal

NA

NA

NA

PR44‡

M

NA

Coronary

Normal

NA

NA

NA

PR45‡

M

NA

Coronary

Normal

NA

NA

NA

  1. * PR of atherosclerotic carotids from E-MEXP-268, a study performed on carotid bilateral stenosis in which the two carotids (indicated by couple of consecutive numbers in the Table) of four independent patients have been analyzed. † PR of normal coronaries from GSE3526 (GSM80609, GSM80610, GSM80631). ‡ PR of normal coronaries from GSE7307 (GSM176115, GSM175820, GSM175821). ICR: index of cardiovascular risk; LAD: Left Anterior Descendent Coronary; AB: Arterial Blood; DCM/ctrl: Dilated Cardiomyopathy, used as pooled controls for microarray experiments; D: Diuretics; AAP: Anti-arrhythmics; AC: Anti-coagulants; HYR: Hypertension regulators; BB: Beta-blockers; ACEH: ACE inhibitors; ST: Statins; CDR: Cholesterol down-regulators; SI: Synthetic insulin; LD: Levodopa; PAH: Pulmonary hypertension; T2D: Type-2-diabetes; HY: Hypertension; HYCH: Hypercholesterolemia; PD: Parkinson's disease; AD: Artery disease; NA: not available.